Invictus MD (CSE:IMH, OTC:IVITF) reports that Future Harvest Development Ltd. (of which Invictus MD currently owns 82.5%) has generated $1.578 million in revenue.
Marijuana Industry
SeeThruEquity Issues Update on ChineseInvestors.com (CIIX), Increases Price Target to $3.75
Less than two weeks after making a presentation at the SeeThruEquity Conference in Miami Beach, SeeThruEquity increased its price target for ChineseInvestors.com (OTCQB: CIIX) to $3.75.
Organigram Recall is a Huge Opportunity for Investors
Organigram (TSX.V:OGI, OTCQB:OGRMF) began a voluntary recall of a total of 74 products produced between February 1 and December 16, 2016. These lots tested positive for two pesticides that aren't authorized for use on cannabis plants under the Pest Control Products Act but there are long-term benefits for the recall.
Invictus MD Inc. Aquiring Canadian Companies in Preparation of Canadian Legalization
Invictus MD Strategies Inc. (CSE:IMH,OTC:IVITF) has a flurry of recent developments as the company builds a portfolio of Canadian licensed producers preparing to move into the recreational market.
The Canadian Bioceutical Corp. Signs up Market Maker
The Canadian Bioceutical Corporation (CSE:BCC,OTC:CBICF) announces that it has entered into a Market Making Services Agreement with Venture Liquidity Providers Inc. for an initial 12 month term.
AusCann (OTCPK:ACNNF) Set To Lead The Australian Marijuana Market
AusCann recently went public via a reverse takeover on the ASX. Their joint-venture with Daya Foundation in Chile and Canopy Growth in Canada puts them at the head of the pack in the Australian market. Canopy Growth Corporation will potentially make the move to buy AusCann.
PotNetwork Holdings, Inc. (POTN) Creating the Highest Quality CBD Oil through Supercritical CO2 Extraction Process
CBD is one of over 85 cannabinoids present in the cannabis plant, and, unlike THC, it interacts with our naturally occurring systems without being psychotropic, which means it doesn’t make a person “high”.
Recall on Plants Containing myclobutanil Pesticide in Canada
When heated, myclobutanil is known to create hydrogen cyanide which is extremely poisonous. 3 of the 38 federally licensed marijuana growing companies have had to recall their products due to the presence of the myclobutanil pesticide.
Aurora Cannabis Inc. Heading to Become #1
Aurora Cannabis Inc. (TSXV:ACB) is a high-flying Canadian medical marijuana producer that is slowly creeping up on Canopy Growth Corp. (TSX:WEED) and Aphria Inc. (TSXV:APH). The company has a $787 million market cap, but it could soon break the $1 billion mark later this year.
Colorado to Become First State with Licensed Cannabis Clubs
Colorado is on the brink of becoming the first state with licensed pot clubs. But the details of how these clubs will operate are as hazy as the underground clubs operating already.
The High Risk of Investing in Medical Marijuana Inc.
Shareholders of Medical Marijuana Inc. ($MJNA , a company traded over-the-counter, have had a stellar year. So far, shares are up over 300% since February of last year. So why is this company such a high risk for new Investors?
Emerald Health Therapeutics Inc. (TSX.V:EMH) Projects Annual Sales of $50million
It's a race to riches that has just begun among a handful of Canada’s licensed, industrial-scale medical marijuana growers – each of whom wants to capitalize on in-house IP that can turn cannabis into mainstream medicine. In the quest to find the next GW, Dundee Capital Markets is championing Emerald Heath Therapeutics Inc.
Courtagen Launches New Avantra Genetics Division
Courtagen Life Sciences, Inc., has launched Avantra Genetics. Avantra is dedicated to providing advanced genomic information for functional medicine practices. Patients suffering from functional disorders may experience symptoms such as pain, fatigue, numbness or sensations and gastrointestinal distress that can be severe, chronic or debilitating.
Vinergy Resources Ltd. and MJ Biopharma Announce Major Breakthrough
While the medicinal cannabis industry continues to rapidly advance and expand operations by identifying new leading edge products, leaders are turning towards the expertise and knowledge of other medical sectors, especially with influence from the biopharma sector.
Tetra Bio-Pharma Starts Phase I Clinical Study of Smoked Cannabis.
Tetra Bio-Pharma (CSE: TBP) (CSE: TBP.CN), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain is pleased to announce that Health Canada has approved its Phase I clinical study of smoked cannabis.